ArticleScientific reports2024

Effectiveness of switching to subcutaneous infliximab in inflammatory bowel disease patients with inadequate biochemical response during intravenous administration.

Bokyeong Lee et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.